Suzuki K, Takahashi M, Ito Y, Tsuge I, Motai H, Takeichi Y, Baba S
Department of Otolaryngology, Nagoya City University Medical School, Nagoya, Japan.
Auris Nasus Larynx. 1999 Jan;26(1):33-8. doi: 10.1016/s0385-8146(98)00025-x.
We reported a retrospective review of the clinical records for a 64 year old male patient with bilateral middle ear squamous cell carcinoma (MESCC), and for the five other patients with MESCC treated at our institution during the last 20 years. The patient with bilateral MESCC has survived and remained tumor free for more than 1.5 years after extended radical resection of the secondary tumor combined with intra-arterial and systemic chemotherapy, radiotherapy and immunotherapy. Four patients with unilateral MESCC were treated with multidisciplinary treatment (induction chemotherapy, surgery and radiotherapy), and the remaining patient was treated with radiotherapy and mastoidectomy. Five of the six patients are alive with no evidence of disease. The patient treated with radiotherapy and radical mastoidectomy died of local recurrence 3 years after diagnosis. We suggest that MESCC should be considered when refractory granulation, long-standing otorrhea, otalgia and facial paralysis are observed. Multidisciplinary treatment, including intra-arterial chemotherapy and en bloc resection of the temporal tumor is useful for the treatment of MESCC and will improve the prognosis of patients with this disease.
我们报告了对一名64岁双侧中耳鳞状细胞癌（MESCC）男性患者以及过去20年在我们机构接受治疗的其他5例MESCC患者临床记录的回顾性分析。双侧MESCC患者在对继发肿瘤进行扩大根治性切除并联合动脉内及全身化疗、放疗和免疫治疗后存活，且无肿瘤复发超过1.5年。4例单侧MESCC患者接受了多学科治疗（诱导化疗、手术和放疗），其余1例患者接受了放疗和乳突根治术。6例患者中有5例存活且无疾病证据。接受放疗和根治性乳突切除术的患者在诊断后3年死于局部复发。我们建议，当观察到难治性肉芽、长期耳漏、耳痛和面瘫时，应考虑MESCC。包括动脉内化疗和颞部肿瘤整块切除在内的多学科治疗对MESCC的治疗有用，并将改善该疾病患者的预后。
